Abstract 1464P
Background
Immunotherapy represents an alternative to chemotherapy and clinical trial for squamous cell lung cancer. Due to the underrepresentation of elderly patients in clinical trials, it is not clear whether they derive similar benefit from immunotherapy as their younger patients.
Methods
A retrospective analysis using National Cancer Database (NCDB) was conducted in patients diagnosed with metastatic squamous cell lung carcinoma between 2016 and 2019. Kaplan Meier survival plots were used to examine survival outcome of different age groups: 19-49, 50-79 and 80 and older. Each age group was examined for benefit from chemotherapy (CR), chemotherapy + immunotherapy (CI), immunotherapy (IO), and no treatment (NR). Cox regression analysis was used to identify factors associated with overall survival.
Results
Of the 24,111 patients analyzed, 3,072 were 80 years or older. Patient who received immunotherapy had much better overall survival than those without. The one-year and two- years overall survival in these groups are CI: 52.98%, 18.10%; IO: 46.85%, 16.34%; CR: 40.11%, 10.73% and NR: 11.13%, 3.81% respectively. Although overall survival declined with age, age itself was not responsible for the poor outcome coming with it. No significant interaction effect was found between age and treatment. In multivariate analysis, HR was 1.01; 0.91-1.11; P=0.862 in age 19-49 and HR 1.02; 0.98-1.06, P=0.397 in age 50-79 compared to age 80 year or older (HR 1.0). Different age groups benefited similarly to all treatments. Compared to CR only (HR 1.0), treatment with CI conferred the best survival outcome HR 0.73; 95% CI 0.71-0.76; P<0.001; IO comes in next with HR 0.84 95% CI 0.80-0.88; P<0.001 and NR performed the worst (HR 2.90; 95% CI 2.80-3.0; P<0.001), suggesting that differences in survival is related to factors other than age.
Conclusions
Although immune senescence is of concern in senior patients receiving immunotherapy, older patients with squamous cell lung cancer benefit from treatment with immune therapy and chemotherapy combination, immunotherapy, chemotherapy as much as younger patients. Age itself is not associated with immunotherapy inefficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhonglin Hao, MD.
Funding
In part by the NCI Cancer Center Support Grant P30 CA177558.
Disclosure
Z. Hao: Non-Financial Interests, Institutional, Local PI: Novartis Inc, BeiGene; Other, Personal, Advisory Role: Cardinal Health.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20